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Autoimmune diseases are initiated when patients develop
aberrant T and/or B cell responses against self proteins.
These responses presumably are directed to single
immunogenic epitopes on these proteins. Recent data in
animal models of autoimmune diseases suggest that the
targets of immune responses in autoimmunity do not
remain fixed, but can be extended to include other
epitopes on the same protein or other proteins in the
same tissue, a phenomenon termed ‘‘epitope spreading.’’
The ‘‘epitope spreading’’ phenomenon also applies to
situations in which tissue damage from a primary
inflammatory process causes the release and exposure of
a previously ‘‘sequestered’’ antigen, leading to a secondary
autoimmune response against the newly released antigen.
For many years, both clinical and investigative dermatologistshave noted the linkage of one disease with another,particularly the clustering of autoimmune diseases. In someinstances, an autoimmune disease occurs in association witha second autoimmune disease, whereas in others it occurs
in association with another inflammatory disease. Several hypotheses
have been suggested to explain such intriguing disease associations.
Among these is the hypothesis that autoimmune diseases are genetically
determined. Therefore, the occurrence of one autoimmune disease
heralds a genetic predisposition and susceptibility to develop another
autoimmune disease. While acknowledging the genetic influence on
autoimmune diseases, one must also consider other factors that may
contribute to autoimmunity because identical genetic traits linked with
disease-affected patients may also be present in healthy individuals.
The development of cicatricial pemphigoid, a putative autoimmune
disease, may serve as an example (Ahmed et al, 1991; Chan et al, 1997).
When Stingl and Holubar reported the coexistence of lichen planus
and bullous pemphigoid (BP) (Stingl and Holubar, 1975), and we
reported three patients who developed BP subsequent to lichen planus
(Davis et al, 1991), and five patients who, subsequent to an acute
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In experimental autoimmune animal diseases, ‘‘epitope
spreading’’ seems to have significant physiologic impor-
tance in determining the course and duration of disease.
In this paper, we review the current concepts in animal
models of autoimmune diseases in order to define the
‘‘epitope spreading’’ phenomenon, and we then propose
how this phenomenon might play a significant role in
the development and the course of autoimmune skin
diseases. Hopefully, an understanding of ‘‘epitope
spreading’’ will help the dermatology community to
better understand the pathogenesis of autoimmune skin
diseases and to rationally fashion disease-specific immune
therapy in the future. Key words: antibody-mediated/autoim-
munity/cell-mediated. J Invest Dermatol 110:103–109, 1998
episode of mucosal epithelial injuries due to Stevens–Johnson syndrome,
developed ocular cicatricial pemphigoid (Chan et al, 1991), the
hypothesis that we and Stingl and Holubar put forward was that
the basement membrane zone (BMZ) injuries that occurred during
the inflammatory process of lichen planus or the Stevens–Johnson
syndrome may have exposed the ‘‘hidden’’ antigens to the immune
system, and subsequently induced an autoimmune response against the
BMZ components. Not until the recent investigations employing
animal models of autoimmune diseases, however, has further light been
shed on this hypothesis. These animal models have increased our
understanding of how a primary autoimmune or inflammatory process
can induce a secondary autoimmune response. The autoimmune animal
models allow step-by-step dissection of disease processes and have
successfully documented the phenomenon of autoimmune reaction to
previously ‘‘sequestered’’ antigens that are released from injured tissue
by a primary autoimmune or inflammatory process. This phenomenon
has been termed ‘‘epitope spreading.’’ In this article, we define ‘‘epitope
spreading’’ and provide examples that occur in animal models of
autoimmune diseases. Selected examples of human autoimmune skin
diseases that are possible manifestations of ‘‘epitope spreading’’ are
illustrated. Because experimental autoimmune diseases cannot be
induced in humans for obvious ethical reasons, the examples of ‘‘epitope
spreading’’ in human skin diseases are not documented with the same
scientific vigor as the animal models.
EPITOPE SPREADING: DEFINITION
‘‘Epitope spreading’’ can be defined as a specific autoreactive lympho-
cyte (T or B cell) response to endogenous epitopes, which are distinct
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Figure 1. Model of epitope spreading in chronic cell-mediated and
antibody-mediated autoimmune diseases. The presentation of the primary
(1°) epitope to the T helper cells (Th) leads to cell- or antibody-mediated tissue
injury and release of a secondary (2°) ‘‘new’’ antigen (Ag) or 2° epitope of the
same Ag. The presentation of the 2° epitope to the naı¨ve Th subsequently
leads to the development of cell- or antibody-mediated autoimmunity against
the 2° Ag (or epitope). APC, antigen presenting cells (Langerhans cells,
macrophages, dendritic cells, B cells); Mac., macrophages; PC, plasma cells;
Com., complements; PMN, polymorphic nuclear leukocytes; Eos., eosinophils;
Lym. Tiss., lymphoid tissues; Prolif., proliferation; Differ., differentiation;
MIP1α, macrophage inflammatory protein 1α; IFNγ, interferon-γ; TNFβ,
tumor necrosis factor-β; LT, leukotriene; (1), help. (Vanderlugt and Miller,
1996.)
from and non-cross-reactive with the disease-inducing epitopes, on
the (same or different) proteins secondary to the release of such self
protein during a chronic autoimmune or inflammatory response
(Vanderlugt and Miller, 1996). That means, in essence, that a primary
autoimmune or inflammatory process may cause tissue damage in such
a manner that certain protein components that are immunologically
‘‘hidden’’ from the immune system become ‘‘revealed’’ and evoke a
secondary autoimmune response.
EPITOPE SPREADING: LESSONS FROM ANIMAL MODELS
OF AUTOIMMUNE DISEASES
Animal models of autoimmune diseases have provided much of the
information available concerning the spreading of antigenic epitopes
during the course of autoimmune disease. Unlike human diseases,
animal models provide a system in which autoimmune responses can
be studied in a controlled fashion from the initiation of the response
against self-antigens, even before the clinical symptoms and signs
become apparent, and followed at each stage of disease thereafter. In
these animal models, epitope spreading can be predominantly B cell
(antibody) or T cell mediated. In either case, epitope spreading within
the same protein (intramolecular) and/or to other distinct proteins
(intermolecular) within the same tissue or protein complex has been
observed. Importantly, the data obtained from these animal models
indicate that, not only does the phenomenon of ‘‘epitope spreading’’
exist, it is indeed very important for the clinical manifestations of
autoimmune diseases. Figure 1 is a schematic diagram depicting a
model of epitope spreading in chronic cell-mediated and antibody-
mediated autoimmune diseases.
Epitope spreading in T cell mediated autoimmune responses
within the same protein The most intensively studied of all animal
models of autoimmunity is experimental autoimmune encephalomyel-
itis. In one form of this disease—relapsing experimental autoimmune
encephalomyelitis—relapsing/remitting hind limb paralysis of the
animals can be elicited in SJL/J mice after immunization with proteoli-
pid protein in complete Fruend’s adjuvant. A disease course that is
identical to the disease induced by immunization with whole protein
can be induced by immunization with a small domain of the whole
protein. This small peptide domain, the so-called ‘‘immunodominant
T cell epitope peptide,’’ consists of only 13 amino acids (amino
acid 139–151). As expected, the mice immunized with this peptide
developed a strong T cell proliferative response and delayed type
hypersensitivity response to the inciting peptide; however, at the time
of clinical relapse, these mice demonstrate proliferative and delayed
type hypersensitivity responses to a secondary, ‘‘subdominant epitope’’
of 14 amino acids (amino acid 178–191) that is distinct and at a distance
from the primary immunodominant epitope (McRae et al, 1995).
Interestingly, the induction of tolerance to the secondary subdominant
epitope prior to clinical relapse can prevent ongoing clinical disease
based on autoimmunity to the primary epitope. Thus, not only is
epitope spreading within proteolipid protein evident during the course
of relapsing experimental autoimmune encephalomyelitis, it also seems
to be responsible for the relapsing nature of the disease (Vanderlugt
and Miller, 1996).
Epitope spreading in T cell mediated autoimmune responses
involving different proteins within the same tissue The non-
obese diabetic (NOD) mouse is a model of the human disease, in
which diabetes mellitus occurs spontaneously in inbred NOD mice.
The initial pathology in the pancreas of an NOD mouse is a T cell
immune reaction, at µ4 wk of age, against a specific pancreatic β cell
protein, glutamic acid decarboxylase; however, there is no clinical
manifestations of diabetes at this time. Yet, as this reactivity against β
cell continues, new reactions develop against other β cell proteins
including carboxypeptidase H, insulin, and heat shock protein 65. It
is only after the spread of immune reactivity to the proteins other than
the original target (glutamic acid decarboxylase) has occurred that
insulitis (massive cellular infiltration of the pancreatic islets) and clinical
diabetes develops (Kaufman et al, 1993; Tisch et al, 1993). Thus, as in
the case of relapsing experimental autoimmune encephalomyelitis,
epitope spreading may play a role in the development of spontaneous
diabetes in the NOD mouse model.
Epitope spreading in autoantibody-mediated autoimmune
response Patients with systemic lupus erythematosus are well known
to have autoantibodies directed against multiple epitopes of the
Ro/La ribonucleoprotein complex and against spliceosomes. Clinical
disease in the form of a systemic lupus erythematosus–like syndrome
(manifested with proteinuria and cytopenia, and the presence of
antinuclear antibodies) can be elicited in mice by immunization of a
human spliceosome peptide. In the mice immunized with spliceosome
protein, or in mice immunized with the human La protein, the original
antibody response against either of the immunized peptides quickly
spreads to other regions of these complexes, leading to a multi-epitope
immune response (James et al, 1995; Topfer et al, 1995). Thus, the
initial singular peptide antibody response spread to other proteins that
could account for the strikingly variable antibody responses against
numerous proteins commonly seen in human patients with systemic
lupus erythematosus.
EPITOPE SPREADING: LESSONS FROM HUMAN
AUTOIMMUNE SKIN DISEASES
Epitope spreading resulted from injuries in autoimmune
dermatoses
Intramolecular (intra-protein) epitope spreading
Pemphigus vulgaris Pemphigus vulgaris is a blistering disease character-
ized by autoantibodies directed against desmoglein 3, an important
structural component of epidermal desmosomes. Clinically, this disease
frequently begins with oral lesions and later progresses to diffuse
involvement of the skin. Recently, it has been observed that patients
with lesions restricted to the mucosa have antibodies that recognize
specific epitopes of desmoglein 3. These autoantibodies do not cross-
react with the pemphigus foliaceus antigen, desmoglein 1, and are
generally not able to induce blister in neonatal mice in passive
transfer experiments; however, in patients with mucocutaneous lesions
autoantibodies, which recognize a secondary and distinct epitope on
desmoglein 3 and are cross-reactive to desmoglein 1, are detected.
And these autoantibodies are able to induce blister in neonatal mice.
Thus, in patients whose disease has progressed from mucosal pemphigus
to mucocutaneous pemphigus, epitope spreading has likely occurred
which accounts for the heterogenous antibody response seen in these
patients. One could envision that the autoimmune reaction against
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specific desmoglein 3 epitope on mucosae may have induced injuries
and exposed a secondary ‘‘new’’ desmoglein 3 epitope to the autoreac-
tive lymphocytes, leading to autoimmune reaction against the secondary
epitope, which is apparently present in the skin and shares significant
homology with desmoglein 1. Thus, these data suggest that the
evolution of the heterogenous antibody response to desmoglein 3 may
account for the progression of disease seen in patients with pemphigus
vulgaris (Ding et al, 1997).
Epidermolysis bullosa acquisita Patients with epidermolysis bullosa acqui-
sita have IgG autoantibodies against epidermolysis bullosa acquisita
antigen (type VII collagen). These autoantibodies target the noncolla-
genous globular amino terminal domain termed NC1 and do not
recognize the collagenous helical portion of the molecule, nor the
noncollagenous globular domain (NC2) at the carboxyl terminus
(Gammon et al, 1993; Lapiere et al, 1993). As suggested by many
examples of autoimmune disease models in animals (Lehmann et al,
1992; McRae et al, 1995), the original development of autoimmunity
to type VII collagen in epidermolysis bullosa acquisita patients likely
involved primarily or exclusively a single antigenic epitope within the
NC1 domain. Nevertheless, Gammon et al (1993), Lapiere et al (1993),
and Tanaka et al (1994) have documented that ‘‘epitope spreading’’
occurs in cases of epidermolysis bullosa acquisita. All three laboratories
have reported that the serum from a single epidermolysis bullosa
acquisita patient contained IgG autoantibodies that recognized multiple
regions of the NC1 domain (Gammon et al, 1993; Lapiere et al, 1993;
Tanaka et al, 1994). The mechanism of ‘‘epitope spreading’’ in this
situation may be very similar to that envisioned in animal models.
Bullous pemphigoid Assuming that autoimmunity against the BP anti-
gens located in the upper lamina lucida/hemidesmosome also initially
involved predominantly or exclusively a single antigenic epitope,
studies have suggested that epitope spreading occurs in BP. Using
recombinant proteins, synthetic peptides, or blocking methods, Rico
et al, Tanaka et al, and Sugi et al have demonstrated that a single BP
patient’s serum containing IgG autoantibodies that are able to recognize
multiple epitopes within the 230 kDa glycoprotein designated as BP
antigen 1 (Sugi et al, 1989; Rico et al, 1990; Tanaka et al, 1991).
Similarly, intraprotein epitope spreading may occur in some cases of
autoimmunity against the BP antigen 2, a 180 kDa protein with an
extracellular collagenous domain (Balding et al, 1996). If the same
assumption holds, interprotein epitope spreading also occurred in BP,
because many BP patients have IgG autoantibodies against both BP230
and BP180 (Labib et al, 1986) that are products of two completely
different genes located on two separated chromosomes. The mechanism
of this type of ‘‘epitope spreading’’ is probably identical or very similar
to that described in animal models (Lehmann et al, 1992; McRae
et al, 1995).
Intermolecular (inter-protein) epitope spreading
Pemphigus vulgaris conversion to pemphigus foliaceus One very illustrative
example of epitope spreading was reported in patients who initially
developed pemphigus vulgaris with typical clinical manifestations,
histopathology, immunopathology, and autoantibodies to desmoglein
3; and who later converted to pemphigus foliaceus. This conversion
to pemphigus foliaceus was associated with an alteration of the
pemphigus vulgaris clinical phenotype towards the phenotype of
pemphigus foliaceus with typical clinical manifestations, histopathology,
immunopathology, and autoantibodies to desmoglein 1 (Kawana et al,
1994). The interesting and puzzling aspect of these cases is why the
disease phenotype was changed from a severer form of disease to a
milder form, as a result of ‘‘epitope spreading.’’
Linear IgA bullous dermatosis with autoantibodies to BP antigen 1 Linear
IgA bullous dermatosis is an IgA-mediated blistering skin disease
characterized by subepidermal blisters and a neutrophilic infiltration
along the skin BMZ (Wojnarowska et al, 1988; Cohen et al, 1997).
Although the target antigen in linear IgA bullous dermatosis was
initially thought to be a distinct BMZ component (Zone et al, 1990),
more recent evidence suggests that the target antigen for these IgA
autoantibodies is an epitope within the extracellular portion of the 180
kDa BP antigen 2 (Pas et al, 1997).1,2 It has also been demonstrated
that IgG class autoantibodies may be involved (Zone et al, 1994; Chan
et al, 1995; Darling et al, 1995). Moreover, it has been shown that IgG
or IgA circulating autoantibodies from these patients also recognized
the 230 kDa BP antigen 1, in addition to the 180 kDa BP antigen 2
(Collier et al, 1994; Chan et al, 1995; Darling et al, 1995). This initial
autoimmunity to the BP antigen 2 that then expands to involve BP
antigen 1 is consistent with the concept of ‘‘epitope spreading.’’
BP with autoantibodies to another basement membrane antigen p105 BP
is characterized histopathologically by subepidermal blister and an
inflammtory cell infiltrate along the skin BMZ that is rich in eosinophils
(Cohen et al, 1997). The initial injury caused by the subepidermal
blistering process may expose other skin BMZ components to auto-
reactive lymphocytes, and subsequently lead to autoimmune response
against another BMZ protein termed p105, located in the lower lamina
lucida (Chan et al, 1993; Cotell et al, 1994).
Systemic lupus erythematosus associated with epidermolysis bullosa
acquisita Systemic lupus erythematosus is a systemic autoimmune
disease characterized by the development of autoantibodies against
multiple self proteins in various tissues. Some patients with systemic
lupus erythematosus have immunoglobulins deposited at the skin BMZ
despite the absence of overt skin lesions, i.e., a positive lupus band.
Presumably, the immune deposits at the skin BMZ could result in
subclinical injury, and expose the anchoring fibril (type VII collagen)
to the autoreactive lymphocytes, which ultimately sensitized and
invoked autoimmunity to type VII collagen and produced a disease
phenotype similar to epidermolysis bullosa acquisita (Gammon et al,
1985; Barton et al, 1986; Yell et al, 1995).
Epitope spreading resulted from injuries in inflammatory
dermatoses and other inflammatory diseases
Lichen planus associated with BP Lichen planus is an idiopathic chronic
inflammatory skin disease characterized histopathologically by a band-
like dermal infiltrate of predominantly lymphocytes along the skin
BMZ and liquefaction degeneration of basal keratinocytes (Toussaint
and Kamino, 1997). These pathologic injuries in lichen planus perturb
the skin BMZ (Smoller and Glusac, 1994; Marren et al, 1994). Thus,
this inflammatory process may expose skin BMZ components to
autoreactive lymphocytes that then induce autoimmunity against skin
BMZ components, such as the BP antigens (Stingl and Holubar, 1975;
Sobel et al, 1976; Hintner et al, 1979). Clinical BP with autoantibodies
against the BP antigens have been documented in such patients (Davis
et al, 1991; Tamada et al, 1995). Figure 2 illustrates another example:
a patient who had a long history of lichen planus with characteristic
nonbullous poligonal papules and plaques and then developed a new
blistering disease. The new blistering disease had features identical to
those of BP as documented by histopathology, linear IgG deposits at
the patient’s perilesional skin BMZ, and circulating IgG autoantibodies
that bound to the epidermal side of salt-split skin and labeled the
180 kDa BP antigen 2 (Fig 2).
Psoriasis associated with BP and pemphigoid-like blistering disease Psoriasis
is a chronic inflammatory and hyperproliferative skin disease character-
ized histopathologically by dermal and epidermal inflammatory infiltra-
tion (Toussaint and Kamino, 1997). These inflammatory cells include
neutrophils, activated T cells and macrophages (a professional antigen
presenting cell), and perivascular dendritic cells (Stingl et al, 1977;
Baadsgaard et al, 1989, 1990; Morganroth et al, 1991). In addition to
the inflammatory and hyperproliferative characteristics, psoriasis skin is
easily injured with even gentle removal of scale over a psoriasis lesion
1Zone JJ, Taylor TB, Meyer LJ, Petersen MJ: The 97-kDa linear IgA bullous
disease antigen is a portion of the extracellular domain of the 180-kDa bullous
pemphigoid antigen. J Invest Dermatol 108:563, 1997 (abstr.)
2Tran HH, Schumann H, Balding S, Giudice GJ, Bruckner-Tuderman L,
Marinkovich MP: LAD-1 is a collagenous component of keratinocyte adhesion
complexes which assembles into a high molecular weight complex and which
has homology to BP180. J Invest Dermatol 108:586, 1997 (abstr.)
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Figure 2. Lichen planus associated with BP. Western blot analyses detected
a 180 kDa BP antigen recognized by the IgG autoantibodies from a patient
affected with lichen planus (lane 2) who subsequently developed a new blistering
disease with IgG autoantibodies that label the epidermal side of salt-split skin
substrate. Controls include sera from two BP patients (lanes 1 and 3) and serum
from a normal volunteer (lane 4).
resulting in dermal bleeding, so-called Auspitz sign (Toussaint and
Kamino, 1997). Furthermore, neutrophil elastase, identified along the
BMZ of psoriatic lesional skin, could play a role in the destruction of
the epidermal–dermal junction (Glinski et al, 1990). One could
envision that the combination of psoriatic injuries caused by chronic
inflammation, the trafficking of activated lymphocytes, and the abund-
ance of antigen presenting cells could expose BMZ components to
autoreactive lymphocytes and induce autoimmunity against these BMZ
components, such as the BP antigens. Such autoimmune reaction may
then subsequently lead to autoimmune disease BP. As reported by
Grattan, seven patients developed BP after the onset of psoriasis from
1 to 30 y (Grattan, 1985). Kirtschig et al also reported four patients
who, after a long history of psoriasis, developed BP with circulating
autoantibodies against the BP antigens (Kirtschig et al, 1996). Figure 3
illustrates another clinical example, in which the patient had a long
history of psoriasis with characteristic nonbullous sharply demarcated
scaly plaques predmoninantly on her extensor surfaces, and then
developed a new blistering disease after receiving a course of Psoralen-
UVA treatment. The new blistering disease had features identical to
those of BP as documented by histopathology, in situ and circulating
IgG autoantibodies that bound to the skin BMZ, and circulating IgG
autoantibodies that recognized the 230 kDa BP antigen 1 (Fig 3).
BMZ injuries induced by ultraviolet light in psoriasis patients receiving
Psoralen-UVA treatments may promote the exposure of BMZ compon-
ents to autoreactive lymphocytes (Thomsen and Schmidt, 1976; Abel
and Bennett, 1979; Kirtschig et al, 1996). In addition, primary psoriasis
has also been linked to the development of a secondary BP-like
blistering disease 20 y after the onset of psoriasis. This blistering disease
is characterized by IgG autoantibodies targeting a undefined 200 kDa
lower lamina lucida component (Chen et al, 1996).
Stevens–Johnson syndrome associated with secondary onset of cicatricial
pemphigoid Stevens–Johnson syndrome is an acute inflammatory dis-
ease involving mucous membranes and skin. Histopathologically, the
acute lesion has a mononuclear cell infiltration along the skin BMZ,
hydropic degeneration of basal keratinocytes, and subepidermal blisters
(Cohen et al, 1997). Chan et al have reported five patients who, after
an acute episode of Stevens–Johnson syndrome, developed chronic
ocular scarring inflammation confirmed to be cicatricial pemphigoid
(Chan et al, 1991). In this scenario, one could envision that the initial
pathologic injuries associated with florid Stevens–Johnson syndrome
released skin BMZ components and exposed them to autoreactive
lymphocytes and induced autoimmunity against these structural self
proteins. Figure 4 illustrates one of these cicatricial pemphigoid patients
(Chan et al, 1991). A patient was also reported to develop cicatricial
pemphigoid 5 y after the onset of a primary chronic inflammtory skin
Figure 3. Psoriasis associated with BP. Clinical observation of new onset
of BP in a patient with long history of psoriasis (a). Histopathology confirmed
the diagnosis of BP in the blister (curved →) in association with psoriasis plaques
(straight →). The diagnosis of BP was further documented by linear IgG
deposition in the patient’s peri-blister skin BMZ and by patient’s circulating
IgG autoantibodies that bound to skin BMZ (b) and recognized a 230 kDa BP
antigen by western blot [c, lane 2 was reacted with this patient’s serum, lanes 1
and 3 were reacted with sera from two BP patient controls, normal human
serum showed negative reaction (not shown)].
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Figure 4. Stevens–Johnson syndrome associated with cicatricial
pemphigoid. Histopathology documented the occurence of primary Stevens–
Johnson syndrome (a) that affected a patient who 6 mo later developed a
secondary chronic inflammatory scarring ocular disease (b). At the time of acute
episode of Stevens–Johnson syndrome, extensive eosinophilic necrosis of
keratinocytes, prominent mononuclear cell infiltration, and hydropic
degeneration of the basal keratinocytes were observed (a). At the time of
chronic ocular disease, biopsy showed linear IgG (c) deposition at the basement
membrane. The patient had a high titer (1:2560) of circulating anti-basement
membrane IgG autoantibodies that recognized a 120 kDa epidermal antigen
(Chan et al, 1991).
disease, lichen sclerosis et atrophica, a condition characterized by
inflammatory cell infiltration and skin BMZ disruption (Marren et al,
1996, 1997).
Dermatitis herpetiformis associated with autoantibodies against BP
antigens Dermatitis herpetiformis is a pruritic inflammatory blistering
skin disease characterized histopathologically by subepidermal separation
and a prominent neutrophilic infiltration along the papillary dermis of
the skin BMZ (Cohen et al, 1997). Although IgA is deposited high
within the papillary dermis juxtaposed to the skin BMZ, circulating
autoantibodies to skin BMZ components are not detected. Therefore,
it does not fulfill the complete criteria for an autoimmune disease
(Rose and Bona, 1993), and, for the purpose of this paper, will be
classified as an inflammatory disease. Within the setting of primary and
chronic dermatitis herpetiformis, there have been several documented
cases of BP autoantibodies developing from 4 mo to 5 y after the onset
of dermatitis herpetiformis (Sander et al, 1989; Setterfield et al, 1997).
One plausible explanation for these occurrences would be that the
neutrophilic inflammation inherent in dermatitis herpetiformis per-
turbed the BMZ and lead to exposure of BMZ components to
autoreactive lymphocytes and autoimmunity against the BP antigens.
Discoid lupus erythematosus associated with autoantibodies against BP
antigens Discoid lupus erythematosus is a cutaneous form of lupus
characterized histopathologically by liquefaction degeneration of basal
keratinocytes and a patchy lymphocytic infiltration around the BMZ
of adnexal structures (Jaworsky, 1997). Ishikawa et al have documented
the occurrence of autoantibodies to BP antigens developing after the
onset of discoid lupus erythematosus (Ishikawa et al, 1997). Presumably,
the chronic BMZ injury from the initial discoid lupus erythematosus
releases and exposes BMZ components to autoreactive lymphocytes
and induces autoimmunity against the BP antigens (Marren et al, 1994;
Ishikawa et al, 1997).
Crohn’s disease associated with autoantibodies against type VII
collagen Inflammatory bowel disease, especially Crohn’s disease, is
frequently associated with epidermolysis bullosa acquisita, an auto-
immune disease characterized by autoantibodies against the noncolla-
genous (NC1) domain of type VII collagen (Lapiere et al, 1996). We
recently identified the presence of type VII collagen in the intestinal
epithelial BMZ. Interestingly, a significant number of patients affected
by Crohn’s disease had circulating IgG autoantibodies against the NC1
domain of type VII collagen.3 Moreover, a dog with inflammatory
bowel disease also had a high titer of circulating IgG autoantibody
against the NC1 domain of type VII collagen.3 One could envision
that the inflammation originally invoked by Crohn’s disease could
perturb the intestinal epithelial BMZ in such a way that BMZ
components are exposed and perhaps altered while in close juxtaposition
with antigen presenting cells, and T and B lymphocytes, and this
process results in on-going autoimmunity to type VII collagen.
Ulcerative colitis associated with linear IgA bullous dermatosis and
BP Another inflammatory bowel disease, ulcerative colitis, is known
to be associated with linear IgA bullous dermatosis (Smith and Zone,
1996). A recent study of 70 adult patients with linear IgA bullous
dermatosis in the U.K. revealed a 7.1% prevalence of ulcerative colitis
in the patients affected by linear IgA bullous dermatosis, much higher
than the 0.05% prevalance of ulcerative colitis in the general U.K.
population (Paige et al, 1997). Paige et al documented eight cases of
linear IgA bullous dermatosis preceded by ulcerative colitis by a median
of 6.5 y (Paige et al, 1997). Although there is no literature on the
presence of BP antigens in human colonic epithelial BMZ, Dr. Giudice
had documented the presence of BP antigen 2 in mouse colorectal
epithelial BMZ (Dr. George Giudice, Medical College of Wisconsin,
personal communication). As in the case of autoantibodies against
3Chen M, O’Toole EA, Sanghavi J, Mahmud N, Kelleher D, Woodley DT:
Type VII (anchoring fibril) collagen exists in human intestine and serves as an
antigenic target in patients with inflammatory bowel disease. J Invest Dermatol
108:542, 1997 (abstr.)
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type VII collagen in Crohn’s disease, one could envision that the
inflammation originally invoked by ulcerative colitis could perturb the
intestinal epithelial BMZ in such a manner that BMZ components are
exposed while in close juxtaposition with antigen presenting cells, and
T and B lymphocytes, and this process thus results in on-going
autoimmunity to linear IgA bullous dermatosis antigen (now part of
BP antigen 2). In addition, BP has been reported to develop in patients
who suffered from ulcerative colitis for a period ranging from 3 to 20
y before the onset of BP (Barth et al, 1988; Harrison et al, 1996).
CONCLUSION
In this paper, we define the autoimmune phenomenon termed ‘‘epitope
spreading’’ and provide examples of this phenomenon in animal models
of autoimmune diseases and selected examples of human autoimmune
skin diseases. Whereas the molecular events in which ‘‘epitope
spreading’’ occurs in human autoimmune skin diseases remain to be
elucidated, we hypothesize that skin injuries from autoimmune or
inflammatory processes could induce autoimmunity to a normally
‘‘sequestered’’ antigen (or epitope). This hypothesis is consistent with
at least two general principles regarding the development of auto-
immunity. First, an autoimmune or inflammatory event is capable of
bringing all the neccessary components together at a localized tissue
site for autoimmunity to be promoted and expanded. These components
include: the autoantigen (the skin components: desmosomal or BMZ
components), antigen presenting cells (Langerhans cells, macrophages,
B cells, and other dendritic cells), and possibly autoreactive lymphocytes,
an environment for optimal antigen presentation. Second, the distressed
skin cells involved in the primary autoimmune or inflammatory process
may have triggered a ‘‘danger’’ signal. These ‘‘danger’’ signals are
essential to activate the antigen presenting cells that in turn deliver
two activating signals, the MHC-peptide and the co-stimulatory
molecules, i.e., B7–1 and B7–2, that promote interaction between
antigen presenting cells and autoreactive lymphocytes in the induction
of autoimmunity (Matzinger and Fuchs, 1996).
The contents of this paper are not meant to be inclusive. Nevertheless,
the examples provided are sufficient to illustrate how ‘‘epitope
spreading’’ might occur in human autoimmune skin diseases. As it is
not possible for ethical reasons to dissect the step-by-step mechanisms of
the ‘‘epitope spreading’’ phenomenon occurring in human autoimmune
skin diseases, confirmation will have to come from active animal disease
models. It is the hope of the authors that this subject will alert the
dermatology community to this interesting autoimmune phenomenon
and that this information will ultimately benefit the dermatology
community in the understanding and treatment of autoimmune skin
diseases.
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